Following a negative FDA advisory committee vote earlier this year, the other shoe has dropped for Lundbeck and Otsuka ...

With a fresh endorsement from the FDA, Johnson & Johnson has rounded out Tremfya’s presence in inflammatory bowel disease ...

As Halloween approaches, Exact Sciences is warding off a particularly terrifying occurrence: skipping colorectal cancer ...

With a Sept. 29 deadline looming for pharmaceutical companies to adhere to President Donald Trump’s Most Favored Nation drug ...

AI is now the first place people go to for answers,” according to Jesse Wolfersberger, global lead of I/O Health at Weber ...

Stealth’s injection, known as elamipretide, will be sold as Forzinity for the treatment of Barth syndrome, an X-linked ...

Kennedy Jr.’s purge of the committee—seemed to contradict themselves when it came time to vote on a vaccine recommendation.

The Centers for Disease Control and Prevention (CDC) has come out with a strong recommendation for the use of Gilead Sciences ...

Eli Lilly has been censured by the U.K. marketing watchdog after a complainant reported being hit by a “bombardment of spam.” ...

Bristol Myers Squibb is exiting the first U.S.-China pharmaceutical joint venture. Kalexo Bio and Ollin Biosciences have ...

Over the last six years, three GLP-1 drugs have been approved for children aged 10 and older with Type 2 diabetes. | Over the ...

The duel of the GLP-1 data sets continues this week, with Novo issuing the latest salvo of updates on its oral obesity ...